Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial

Jean Yves Blay; Sylvie Chevret; Axel Le Cesne; Mehdi Brahmi; Nicolas Penel; Sophie Cousin; François Bertucci; Emmanuelle Bompas; Thomas Ryckewaert; Pauline Soibinet; Pascaline Boudou‐Rouquette; Esma Saada Bouzid; P Soulié; Thibaud Valentin; Jean‐Pierre Lotz; Diégo Tosi; Zoé Nevière; Mathilde Cancel; Isabelle Ray‐Coquard; Laëtitia Gambotti; Frédéric Legrand; Assia Lamrani-Ghaouti; Clotilde Simon; Caroline Even; Christophe Massard

doi:10.1016/s1470-2045(23)00282-6

Related publications

Article2018

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu, Richard S. Finn, Julien Edeline, Stéphane Cattan, Sadahisa Ogasawara, Daniel H. Palmer, Chris Verslype, Vittorina Zagonel, Lætitia Fartoux, Arndt Vogel, Debashis Sarker, Gontran Verset, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Andrea L. Webber, Scot Ebbinghaus, Junshui Ma, Abby B. Siegel, Ann‐Lii Cheng, Masatoshi Kudo, Angela Alistar, Jamil Asselah, Jean–Frédéric Blanc, Ivan Borbath, Timothy Lewis Cannon, Ki Y. Chung, Allen Lee Cohn, David Cosgrove, Nevena Damjanov, Mukul Gupta, Yoshivasu Karino, Mark Karwal, Andreas Kaubisch, Robin Kate Kelley, Jena-Luc Van Laethem, Timothy Larson, James Lee, Daneng Li, Atisha Manhas, Gulam A. Manji, Kazushi Numata, Benjamin M. Parsons, Andrew Scott Paulson, Carmine Pinto, Robert A. Ramirez, Suresh Ratnam, Magnus Rizell, Olivier Rosmorduc, Yvonne H. Sada, Yutaka Sasaki, Per Stål, Simone I. Strasser, Joerg Trojan, Gina M. Vaccaro, Hans Van Vlierberghe, Alan Weiss, Karl-Heinz Weiss, Tatsuya Yamashita

Article2021

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, Anthony M. Joshua, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian Kirkwood, Siobhan Ng, Roslyn J. Francis, Craig Gedye, Natalie Rutherford, Andrew Weickhardt, Andrew M. Scott, Sze-Ting Lee, Edmond M. Kwan, Arun Azad, Shakher Ramdave, Andrew D. Redfern, W A Macdonald, Alex Guminski,

Article2022

Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort

Antoîne Italiano, Alban Bessede, M. Pulido, Emmanuelle Bompas, Sophie Piperno‐Neumann, Christine Chevreau, Nicolas Penel, François Bertucci, Maud Toulmonde, Carine Bellera, Jean‐Philippe Guégan, Christophe Rey, Catherine Sautès‐Fridman, Antoine Bougoüin, Coralie Cantarel, Michèle Kind, Mariella Spalato Ceruso, Bérengère Dadone‐Montaudié, François Le Loarer, Jean Yves Blay, Wolf H. Fridman

Article2019

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

Joaquı́n Mateo, Núria Porta, Diletta Bianchini, Ursula McGovern, Tony Elliott, Robert J. Jones, Isabel Syndikus, Christy Ralph, Suneil Jain, Mohini Varughese, Omi Parikh, Simon J. Crabb, Angus Robinson, Duncan B. McLaren, Alison Birtle, Jacob Tanguay, Susana Miranda, Ines Figueiredo, George Seed, Cláudia Bertan, Penny Flohr, Berni Ebbs, ,

Article2020

538P Vemurafenib in non-melanoma V600 and non-V600 BRAF mutated cancers: Results of the AcSé basket trial

Pascale Tomasini, Julien Mazières, Claire Cropet, Xavier Troussard, David Malka, Isabelle Laure Ray-Coquard, Sophie Leboulleux, Aude Fléchon, Bertrand Arnulf, Mathilde Cancel, Ivan Bièche, S. Collot, S. Taïeb, Gabriel Garcia, A.M. Mandache, N. Colignon, Marie Gavrel, Marta Jimenez, Natalie Hoog-Labouret, Jean Yves Blay